藥明康德(02359.HK)重申業務發展不會對國家安全構成風險 澄清無贊助軍民融合項目
藥明康德(02359.HK)受美國眾議院的《生物安全法案》草案傳聞打擊,上周五(26日)藥明系股價顯著下跌。公司於周五晚上隨即召開投資人電話會議,重申業務發展並不會對任何國家安全構成風險。
公司管理層又澄清,從來無贊助過涉軍計劃或軍民融合項目,亦無直接收到過任何相關基金的直接投資,但表示作為一家上市公司,任何個人和投資機構都可以在二級市場上購買和出售公司的流通股票。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.